论文部分内容阅读
The purpose of the current study is to evaluate the clinical value of <18>F- fluorodeoxyglucose PET/CT on detecting post-operative recurrence in patients with esophageal cancer. Methods 37 post-operative patients with esophageal cancer underwent PET/CT scans from June 2003 through August 2005 to detect recurrent disease; a final diagnosis was reached by the histopathology or clinical follow-up of at least 6 months. The diagnostic sensitivity, specificity, and accuracy of
PET/CT were assessed at local, regional and distant sites, as well as overall estimate for a composite of all the above sites. The false-positive and false- negative results of PET/CT were analyzed as well. Results 31 out of 37 patients were finally confirmed with recurrence in a total of 46 sites. There were six false-positive findings in PET/CT reports
involving two sites at esophagogastric anastomosis, one near the back wall of gastric pull-up, two at hilar lymph nodes, and one in left lower lung. There were three false-negative PET/CT interpretations including one subcarina lymph node, one paratracheal lymph node and one metastatic lesion in the right lower lung. The overall sensitivity, specificity and
accuracy of PET/CT for detecting recurrence were 93.5%(43/46), 76.9%(20/26) and 87.5% (63/72), respectively. On a site-based analysis, it was found that only the specificity at local sites was lower (50%) because of a high rate of false-positive
findings (3 cases in 6). In contrast, PET/CT had excellent performance both at regional and distant sites, the sensitivity, specificity and accuracy were 86.7%, 84.6% and 85.7% for regional recurrence, versus 95.5%, 85.7% and 93.1% for distant metastasis, respectively. Conclusion <18>F-FDG PET/CT is highly effective in detecting regional and distant recurrence for post-operative patients with esophageal cancer. However the specificity was rather low at local area due to a high rate of positive findings, particularly at anastomosis, endoscopy is essential to reach a final diagnosis in this instance.